Psychologists in Rhinelander, WI Accepting Medicare

9 Psychologists found. Showing 1 - 9

Dr. Jamie Hein, PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1020 Kabel Ave, Rhinelander, WI 54501 Phone: 715-361-2805

Demara B Bennett Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000    Fax: 715-361-2877

Dr. Kayleena Kelly, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1020 Kable Ave, Rhinelander, WI 54501 Phone: 715-361-2805    Fax: 715-361-2920

Dr. Shawn Ann Pflugardt, PSY.D. Psychologist - Clinical Medicare: Accepting Medicare Assignments Practice Location: 1020 Kabel Ave, Rhinelander, WI 54501 Phone: 715-361-2805

Gina K Koeppl, PHD Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000    Fax: 715-361-2877

Susan L Stacy Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2251 N Shore Dr, Rhinelander, WI 54501 Phone: 715-361-2000    Fax: 715-361-2877

Michael L Galli, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1831 N Stevens Street, Rhinelander, WI 54501 Phone: 715-365-7000    Fax: 715-365-7029

Danielle N Zayia, MS Psychologist Medicare: Medicare Enrolled Practice Location: 1020 Kabel Ave, Rhinelander, WI 54501 Phone: 715-361-2805

Dr. Stephanie Ann Pittman, ED.D. Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 21 S Brown St, Rhinelander, WI 54501 Phone: 715-362-5437

News Archive

UVA researchers find biological trigger for protective form of immune response to spinal cord injury

Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response - a vital step toward being able to harness the body's defenses to improve treatment for spine injuries, brain trauma, Alzheimer's disease and other neurodegenerative conditions.

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced on December 13 the initiation of the regulatory process for a Glaucoma Phase II clinical study in Israel. Leading Medical Centers in Israel will enroll 44 patients with Ocular Hypertension or Glaucoma for the first segment of the trial, who will be treated for 16 weeks with CF101 or placebo.

Stroke doubles patients' risk of breaking a hip or femur

Stroke survivors have about twice the risk of breaking a hip or femur compared to those without stroke - and the risk is even greater for younger patients, women and those with recent strokes, Dutch researchers report in Stroke: Journal of the American Heart Association.

Nycomed, Merck enter co-promotion agreement for Daxas in Canada and Europe

Nycomed and Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) today announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast), an investigational once-daily tablet for patients with chronic obstructive pulmonary disease (COPD). In addition, the two companies have signed an exclusive distribution agreement for the commercialization of Daxas® in the United Kingdom.

Nitric oxide good for some prem babies but not for others

According to two new studies, although nitric oxide can halve the risk of developmental problems in premature babies with undeveloped lungs, the gas could be harmful to newborns who are too small and too ill.

Read more Medical News

› Verified 1 days ago